Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2419169 | 0.81 | HCAR2 (0.33) | HCAR2 | |
| SCHEMBL2417632 | 0.79 | CHRNB2 (0.37) | HCAR2 | |
| SCHEMBL2421639 | 0.78 | CYP11B1 (0.41) | — | |
| SCHEMBL2417143 | 0.78 | CYP11B1 (0.38) | CYP2C9 | |
| SCHEMBL14983545 | 0.75 | — | — | |
| SCHEMBL8931090 | 0.74 | HCAR2 (0.36) | ATMHCAR2CYP2A6 | |
| SCHEMBL14983439 | 0.71 | ACHE (0.42) | CYP2C9CYP2C19 | |
| SCHEMBL18417966 | 0.70 | HCAR2 (0.40) | ATMHCAR2CYP2A6 | |
| SCHEMBL4849535 | 0.69 | CHRNB2 (0.40) | CYP2C9CYP2C19CYP2A6 | |
| SCHEMBL30941538 | 0.69 | HCAR2 (0.43) | ATMHCAR2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102282133-A | decahydro-1H-indenoquinolinone and decahydro-3H-cyclopentaphenanthrenone CYP17 inhibitors | — | 2011-12-14 | — | — | CN | disclosed |
| EP-2362872-A2 | DECAHYDRO-1H-INDENOQUINOLINONE AND DECAHYDRO-3H-CYCLOPENTAPHENANTHRIDINONE CYP17 INHIBITORS | BioMarin Pharmaceutical Inc. (US) | 2011-09-07 | — | — | EP | disclosed |
| WO-2010062506-A2 | DECAHYDRO-1H-INDENOQUINOLINONE AND DECAHYDRO-3H-CYCLOPENTAPHENANTHRIDINONE CYP17 INHIBITORS | LEAD THERAPEUTICS, INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100105700-A1 | DECAHYDRO-1H-INDENOQUINOLINONE AND DECAHYDRO-3H-CYCLOPENTAPHENANTHRIDINONE CYP17 INHIBITORS | LEAD THERAPEUTICS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105700-A1 | DECAHYDRO-1H-INDENOQUINOLINONE AND DECAHYDRO-3H-CYCLOPENTAPHENANTHRIDINONE CYP17 INHIBITORS | CYP17A1, HSD17B1, CYP21A2 | ATM 3942/4885HCAR2 1644/4885CYP2C9 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.